Clinical biomarkers directing the management of patients with colon and lung cancer (beyond oncogene-addicted NSCLC)

[1]Meric-Bernstam F, Mills GB. Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol 2012; 9: 542–548.Meric-BernstamFMillsGBOvercoming implementation challenges of personalized cancer therapyNat Rev Clin Oncol2012954254810.1038/nrclinonc.2012.127Search in Google Scholar

[2]Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89–95.Biomarkers Definitions Working GBiomarkers and surrogate endpoints: preferred definitions and conceptual frameworkClin Pharmacol Ther200169899510.1067/mcp.2001.113989Search in Google Scholar

[3]Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.BrayFFerlayJSoerjomataramIGlobal cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA Cancer J Clin20186839442410.3322/caac.21492Search in Google Scholar

[4]Hirsch FR, Scagliotti GV, Mulshine JL et al. Lung cancer: current therapies and new targeted treatments. Lancet 2017; 389: 299–311.HirschFRScagliottiGVMulshineJLLung cancer: current therapies and new targeted treatmentsLancet201738929931110.1016/S0140-6736(16)30958-8Search in Google Scholar

[5]Zielinski C, Knapp S, Mascaux C et al. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Ann Oncol 2013; 24: 1170–1179.ZielinskiCKnappSMascauxCRationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancerAnn Oncol2013241170117910.1093/annonc/mds647Search in Google Scholar

[6]Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540–1550.HerbstRSBaasPKimDWPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet20163871540155010.1016/S0140-6736(15)01281-7Search in Google Scholar

[7]Herbst RS, Baas P, Perez-Gracia JL et al. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. Ann Oncol 2019; 30: 281–289.HerbstRSBaasPPerez-GraciaJLUse of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trialAnn Oncol20193028128910.1093/annonc/mdy545Search in Google Scholar

[8]Reck M, Rodriguez-Abreu D, Robinson AG et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016; 375: 1823–1833.ReckMRodriguez-AbreuDRobinsonAGPembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung CancerN Engl J Med20163751823183310.1056/NEJMoa1606774Search in Google Scholar

[9]Reck M, Rodriguez-Abreu D, Robinson AG et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J Clin Oncol 2019; 37: 537–546.ReckMRodriguez-AbreuDRobinsonAGUpdated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or GreaterJ Clin Oncol20193753754610.1200/JCO.18.00149Search in Google Scholar

[10]Gandhi L, Rodriguez-Abreu D, Gadgeel S et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378: 2078–2092.GandhiLRodriguez-AbreuDGadgeelSPembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung CancerN Engl J Med20183782078209210.1056/NEJMoa1801005Search in Google Scholar

[11]Ready N, Hellmann MD, Awad MM et al. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. J Clin Oncol 2019; JCO1801042.ReadyNHellmannMDAwadMMFirst-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as BiomarkersJ Clin Oncol2019JCO180104210.1200/JCO.18.01042Search in Google Scholar

[12]Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160–1174.CiardielloFTortoraGEGFR antagonists in cancer treatmentN Engl J Med20083581160117410.1056/NEJMra0707704Search in Google Scholar

[13]Schmoll HJ, Van Cutsem E, Stein A et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479–2516.SchmollHJVan CutsemESteinAESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision makingAnn Oncol2012232479251610.1093/annonc/mds236Search in Google Scholar

[14]Di Fiore F, Blanchard F, Charbonnier F et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96: 1166–1169.Di FioreFBlanchardFCharbonnierFClinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapyBr J Cancer2007961166116910.1038/sj.bjc.6603685Search in Google Scholar

[15]Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374–379.LievreABachetJBBoigeVKRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximabJ Clin Oncol20082637437910.1200/JCO.2007.12.5906Search in Google Scholar

[16]Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757–1765.KarapetisCSKhambata-FordSJonkerDJK-ras mutations and benefit from cetuximab in advanced colorectal cancerN Engl J Med20083591757176510.1056/NEJMoa0804385Search in Google Scholar

[17]Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626–1634.AmadoRGWolfMPeetersMWild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerJ Clin Oncol2008261626163410.1200/JCO.2007.14.7116Search in Google Scholar

[18]Bokemeyer C, Van Cutsem E, Rougier P et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48: 1466–1475.BokemeyerCVan CutsemERougierPAddition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trialsEur J Cancer2012481466147510.1016/j.ejca.2012.02.057Search in Google Scholar

[19]Douillard JY, Siena S, Cassidy J et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697–4705.DouillardJYSienaSCassidyJRandomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME studyJ Clin Oncol2010284697470510.1200/JCO.2009.27.4860Search in Google Scholar

[20]De Roock W, Jonker DJ, Di Nicolantonio F et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304: 1812–1820.De RoockWJonkerDJDi NicolantonioFAssociation of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximabJAMA20103041812182010.1001/jama.2010.1535Search in Google Scholar

[21]Tejpar S, Celik I, Schlichting M et al. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012; 30: 3570–3577.TejparSCelikISchlichtingMAssociation of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximabJ Clin Oncol2012303570357710.1200/JCO.2012.42.2592Search in Google Scholar

[22]Kopetz S, Mcdonough S, Lenz H-J et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406) J Clin Oncol. 2017;35(15 Suppl):3505.KopetzSMcdonoughSLenzH-JRandomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)J Clin Oncol20173515 Suppl350510.1200/JCO.2017.35.15_suppl.3505Search in Google Scholar

[23]Kopetz S, Grothey A, Yaeger R et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med 2019; 381: 1632–1643.KopetzSGrotheyAYaegerREncorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal CancerN Engl J Med20193811632164310.1056/NEJMoa1908075Search in Google Scholar

[24]Rachiglio AM, Esposito Abate R, Sacco A et al. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. Oncotarget 2016; 7: 66595–66605.RachiglioAMEsposito AbateRSaccoALimits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinomaOncotarget20167665956660510.18632/oncotarget.10704Search in Google Scholar

[25]Butterfield LH. The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol 2018; 52: 12–15.ButterfieldLHThe Society for Immunotherapy of Cancer Biomarkers Task Force recommendations reviewSemin Cancer Biol201852121510.1016/j.semcancer.2017.09.006Search in Google Scholar

[26]Manicone M, Poggiana C, Facchinetti A et al. Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer. J Thorac Dis 2017; 9: S1346–S1358.ManiconeMPoggianaCFacchinettiACritical issues in the clinical application of liquid biopsy in non-small cell lung cancerJ Thorac Dis20179S1346S135810.21037/jtd.2017.07.28Search in Google Scholar